968-81-0
Chemical Structure
Acetohexamide
- CAS No.: 968-81-0
- Formula:C15H20N2O4S
- Molecular Weight:324.40
IUPAC Name: 4-acetyl-N-(cyclohexylcarbamoyl)benzenesulfonamide
InChIKey: VGZSUPCWNCWDAN-UHFFFAOYSA-N
SMILES: O=S(C1=CC=C(C(C)=O)C=C1)(NC(NC2CCCCC2)=O)=O
Biological Activity: Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action[1][2][3][4].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Acetohexamide | 99.67% | Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acetohexamide (Standard) | ≥98% | Acetohexamide (Standard) is the analytical standard of Acetohexamide. This product is intended for research and analytical applications. Acetohexamide is an orally active first-generation sulfonylurea agent used in research related to type 2 diabetes and cancer. Acetohexamide exerts reductase activity in human erythrocytes. Acetohexamide stimulates the pancreas to secrete insulin. Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. Acetohexamide can inhibit the formation of circular chemorepellent induced defects (CCIDs) in lymphendothelial cell (LEC) monolayers. Acetohexamide inhibits markers of epithelial-to-mesenchymal-transition and migration. Acetohexamide suppresses the synthesis of 12(S)-HETE. Acetohexamide can potentiate hypoglycaemic action. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Acetohexamide-d11 | Acetohexamide-d11 is the deuterium labeled Acetohexamide (HY-B0881). Acetohexamide is a first-generation sulfonylurea agent used in research related to type 2 diabetes; it stimulates the pancreas to secrete insulin.Acetohexamide inhibits ATP-sensitive potassium channels in the β cells of the pancreas. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
- [1]. White JA, et al. Nonhypoglycemic drug reactions of agents used to treat diabetes. Endocrinol Metab Clin North Am. 2000 Dec;29(4):803-11. [Content Brief]
- [2]. Kishimoto, M., et al., (1994). Carbonyl reductase activity for acetohexamide in human erythrocytes. Drug metabolism and disposition: the biological fate of chemicals, 22(3), 367–370. [Content Brief]
- [3]. Kretschy, N., et al., (2013). In vitro inhibition of breast cancer spheroid-induced lymphendothelial defects resembling intravasation into the lymphatic vasculature by acetohexamide, isoxsuprine, nifedipin and proadifen. British journal of cancer, 108(3), 570–578. [Content Brief]
- [4]. Imamura, Y., et al., (1990). Mechanism of pharmacodynamic and pharmacokinetic interactions between acetohexamide and phenylbutazone in rabbits. Pharmacology & toxicology, 67(5), 415–419. [Content Brief]
